Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 24;13(9):e0204413.
doi: 10.1371/journal.pone.0204413. eCollection 2018.

Use of Sedative-Hypnotics and the Risk of Alzheimer's Dementia: A Retrospective Cohort Study

Free PMC article

Use of Sedative-Hypnotics and the Risk of Alzheimer's Dementia: A Retrospective Cohort Study

Joonki Lee et al. PLoS One. .
Free PMC article

Erratum in


There has been a growing interest in the relationship between sedative-hypnotics use and the risk of Alzheimer's dementia (AD) risk. This study aimed to evaluate the risk of AD associated with the use of sedative-hypnotics. A retrospective cohort study was conducted with randomly selected 5% samples from ≥50 years old beneficiaries of National Health Insurance Service (NHIS) of Korea from January 2002 to December 2015. The exposure to sedative-hypnotics was defined when prescribed over 30 defined daily dose (DDD) after January 2004 and it was categorized by prescribed dosage, types and half-lives of benzodiazepines. Time-dependent Cox regression model with a lag period of 5-years was used to evaluate the association between use of sedative-hypnotics and the risk of subsequent AD. Sensitivity analysis was performed for restricting sedative-hypnotics only when prescribed with insomnia. A total of 268,170 subjects were identified and subjects exposed to sedative-hypnotics showed a higher risk of AD (HR: 1.79; 95% CI: 1.72-1.86) than those who were not. There was an increased risk of AD among subjects exposed to benzodiazepines or zolpidem (HR: 1.75; 95% CI: 1.67-1.82) and antidepressants or low-dose antipsychotics (HR: 1.63; 95% CI: 1.42-1.87). The risk of AD was increased regardless of dose of sedative-hypnotics and half-life among benzodiazepines, especially in exposure to more than 360 DDD of sedative-hypnotics (HR: 1.78; 95% CI: 1.60-1.99) and the long-acting benzodiazepine (HR:1.77; 95% CI: 1.65-1.89).

Conflict of interest statement

The authors have declared that no competing interests exist.


Fig 1
Fig 1. Description of follow-up of study population.
Fig 2
Fig 2. Selection of subjects included in the study.

Similar articles

See all similar articles

Cited by 5 articles


    1. Oh S-H, Oh KS, Lee K-U, Woo J-M, Lee B-C, Hwang JS, et al. In-depth investigation for prescribing trends of benzodiazepines in South Korea. Int J Clin Pharmacol Ther. 2014;52(6):460–70. Epub 2014/05/03. 10.5414/CP202008 . - DOI - PubMed
    1. Chung S, Park B, Yi K, Lee J. Pattern of Hypnotic Drug Prescription in South Korea: Health Insurance Review and Assessment Service-National Patients Sample. Sleep Medicine Research. 2013;4(2):51–5. doi: s. PubMed PMID: SC000006407.
    1. Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. Pharmacoepidemiology and Drug Safety. 2016;25(6):637–45. Epub 2015/12/30. 10.1002/pds.3951 ; PubMed Central PMCID: PMCPMC4889508. - DOI - PMC - PubMed
    1. Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. REVIEW ARTICLE. Sleep medicine reviews. 2000;4(1):5–20. Epub 2003/01/18. 10.1053/smrv.1999.0076 . - DOI - PubMed
    1. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs. Journal of General Internal Medicine. 2007;22(9):1335–50. Epub 2007/07/11. 10.1007/s11606-007-0251-z PubMed PMID: PMC2219774; PubMed Central PMCID: PMCPMC2219774. - DOI - PMC - PubMed

Publication types

Grant support

This work was supported by the research fund of Mental Health Technology Development Project (Project No. HM15C1197), ( The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.